Ironwood Pharmaceuticals, Inc.

NasdaqGS:IRWD Stock Report

Market Cap: US$585.7m

Ironwood Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:IRWD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Nov 24SellUS$44,884Sravan EmanyIndividual11,001US$4.08
18 Nov 24SellUS$21,869Andrew DavisIndividual5,360US$4.08
12 Aug 24SellUS$13,267Ronald SilverIndividual3,107US$4.27
12 Aug 24SellUS$42,316John MinardoIndividual9,910US$4.27
07 Jun 24SellUS$517,694Catherine MoukheibirIndividual80,000US$6.61
20 May 24SellUS$112,256John MinardoIndividual17,404US$6.45
20 May 24SellUS$104,026Michael ShetzlineIndividual16,128US$6.45
20 May 24SellUS$436,136Thomas McCourtIndividual67,618US$6.45
20 May 24SellUS$146,576Andrew DavisIndividual22,725US$6.45
06 Mar 24BuyUS$60,204Jon DuaneIndividual6,920US$8.70
04 Mar 24BuyUS$100,216Sravan EmanyIndividual10,684US$9.38
12 Feb 24SellUS$2,699,979Thomas McCourtIndividual177,164US$15.24
12 Feb 24SellUS$150,053Andrew DavisIndividual9,846US$15.24
12 Feb 24SellUS$588,538Michael ShetzlineIndividual38,618US$15.24
12 Feb 24SellUS$722,071John MinardoIndividual47,380US$15.24
12 Feb 24SellUS$120,518Ronald SilverIndividual7,908US$15.24

Insider Trading Volume

Insider Buying: IRWD insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of IRWD?
Owner TypeNumber of SharesOwnership Percentage
State or Government64,8740.0382%
Individual Insiders2,810,9491.65%
Hedge Funds33,187,19819.5%
Institutions133,895,34178.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 86.78% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.3%
BlackRock, Inc.
22,919,857US$83.9m0.19%no data
13.8%
The Vanguard Group, Inc.
22,038,097US$80.7m2.2%no data
10.2%
Sarissa Capital Management LP
16,390,000US$60.0m0%15.15%
7.05%
Pacer Advisors, Inc.
11,279,822US$41.3m26.6%0.09%
6.2%
State Street Global Advisors, Inc.
9,919,865US$36.3m7.32%no data
5.37%
Renaissance Technologies LLC
8,597,198US$31.5m0.3%0.05%
5.12%
Armistice Capital LLC
8,200,000US$30.0m5.13%0.72%
3.16%
LSV Asset Management
5,051,601US$18.5m-16.8%0.04%
2.77%
Braidwell LP
4,438,232US$16.2m0%0.75%
2.67%
Jacobs Levy Equity Management Inc
4,265,100US$15.6m-2.14%0.06%
2.3%
Kynam Capital Management, LP
3,685,563US$13.5m124%1.12%
2.3%
Morgan Stanley, Investment Banking and Brokerage Investments
3,672,661US$13.4m-8.72%no data
2.06%
Geode Capital Management, LLC
3,293,542US$12.1m-2.34%no data
1.19%
Charles Schwab Investment Management, Inc.
1,904,271US$7.0m0%no data
0.94%
Northern Trust Global Investments
1,506,148US$5.5m2.01%no data
0.91%
Jupiter Fund Management Plc
1,448,435US$5.3m0%0.02%
0.87%
Norges Bank Investment Management
1,393,077US$5.1m0%no data
0.79%
Two Sigma Advisers, LP
1,260,500US$4.6m5.13%0.01%
0.76%
UBS Asset Management AG
1,216,609US$4.5m-43.4%no data
0.75%
Argenta Asset Management SA
1,207,997US$4.4m0%0.09%
0.7%
Saturn V Capital Management LP
1,120,409US$4.1m0.59%1.93%
0.67%
Goldman Sachs Group, Investment Banking and Securities Investments
1,080,112US$4.0m-26.6%no data
0.66%
Deutsche Asset & Wealth Management
1,063,199US$3.9m1.53%no data
0.62%
Stonepine Capital Management LLC
1,000,000US$3.7m1,980%1.32%
0.58%
Millennium Management LLC
925,872US$3.4m-30.3%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 18:28
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ironwood Pharmaceuticals, Inc. is covered by 35 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Patrick TrucchioBerenberg
David MarisBMO Capital Markets Equity Research